For years, the Shroyer lab, in collaboration with Escobar-Hoyos, has been exploring K17 as a biomarker for various cancers, including UC and pancre
For years, the Shroyer lab, in collaboration with Escobar-Hoyos, has been exploring K17 as a biomarker for various cancers, including UC and pancreatic cancer.
Furthermore, the research team continues to advance the understanding of how K17, once thought to be only a structural protein, fundamentally impacts numerous hallmarks of cancer.
“We are pleased to report that the test using a K17 biomarker continues to show high sensitivity in identifying both new cancers from hematuria patients and recurrent cancer from patients being monitored for UC,” said doctor Nam W. Kim.
The chief executive officer and chief technology officer of KDx Diagnostics, Inc. also announced: “There is now a growing body of evidence that the non-invasive, K17 urine test will make a significant positive impact on detection and management of UC.”